Uterine Corpus Leiomyosarcoma
NCI Definition: An aggressive malignant smooth muscle neoplasm, arising from the uterine corpus. It is characterized by a proliferation of neoplastic spindle cells. 
Uterine corpus leiomyosarcomas most frequently harbor alterations in TP53, RB1, ATRX, MED12, and PTEN .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, RB1 Loss, and ATRX Mutation are the most common alterations in uterine corpus leiomyosarcoma .
There are 2 clinical trials for uterine corpus leiomyosarcoma, of which 1 is open and 1 is completed or closed. Of the trials that contain uterine corpus leiomyosarcoma as an inclusion criterion, 2 are phase 2 (1 open).
Gemcitabine, olaparib, and pazopanib are the most common interventions in uterine corpus leiomyosarcoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.